Results 51 to 60 of about 28,367 (198)

Emerging bedaquiline resistance: A threat to the global fight against drug-resistant tuberculosis

Journal of Biosafety and Biosecurity
Bedaquiline resistance is increasingly observed in the treatment of rifampicin-resistant tuberculosis (TB), yet standardized regimens for managing bedaquiline-resistant TB are lacking.
Prakasini Satapathy, Ramaiah Itumalla, Ahmad Neyazi, Abdul Mobin Nabizai Taraki, Mahalaqua Nazli Khatib, Shilpa Gaidhane, Quazi Syed Zahiruddin, Sarvesh Rustagi, Mehrab Neyazi   +8 more
doaj   +1 more source

Targeting bedaquiline mycobacterial efflux pump to potentially enhance therapy in Mycobacterium abscessus

International Journal of Mycobacteriology, 2020
Background: Mycobacterium abscessus is notorious for being intrinsically resistant to most antibiotics. Antibiotic efflux is one of the mechanisms used by M. abscessus to pump out antibiotics from their cells.
Anandi Martin, Yasmine Bouyakoub, Kate Soumillion, Eléonore Ngyuvula Mantu, Alexandre Colmant, Hector Rodriguez-Villalobos   +5 more
doaj   +1 more source

Molecular Mechanisms of Resistance and Treatment Efficacy of Delamanid Against Mycobacterium tuberculosis: A Systematic Review

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims Tuberculosis (TB) remains a major global health problem, and treatment progress is increasingly threatened by rising multidrug‐resistant tuberculosis (MDR‐TB). Delamanid (DLM), a nitroimidazole drug, has shown good efficacy and safety against both drug‐susceptible and drug‐resistant Mycobacterium tuberculosis (Mtb) strains.
Md. Mahmudul Islam, Md. Zahid Hasan, Md. Touki Tahamid Tusar, Md. Yeamin Hossain, Md. Motaher Hossain, Md. Abdulla Al Jubayed, Md. Jubaer‐Al‐Abedin, Sheikh Soikot, Shanzida Akther, Jahid Bhuyian, Hafizur Rahman Gazi, B. M. Mahmudul Hasan, Md. Shofiul Azam, Md. Enamul Haque, Abdullah‐Al‐Jubayer, Md. Faruk Hasan, F. M. Ali Haydar, Md. Khalekuzzaman, Md. Torequl Islam, Sohel Hasan   +19 more
wiley   +1 more source

High Prevalence of atpE Mutations in Bedaquiline-Resistant Mycobacterium tuberculosis Isolates, Russia

Emerging Infectious Diseases
Bedaquiline is a cornerstone drug for treating drug-resistant tuberculosis. We analyzed 11 isolates from 9 patients who were treated with a bedaquiline-based regimen and remained culture-positive long after treatment start. In 4 of 8 resistant isolates,
Danila Zimenkov, Anastasia Ushtanit, Elizaveta Gordeeva, Elena Guselnikova, Yakov Schwartz, Natalia Stavitskaya   +5 more
doaj   +1 more source

Randomized, Placebo‐Controlled, First‐in‐Human Study of the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Oral Doses of Novel Antitubercular Drug Candidate, GSK2556286, in Healthy Adults

The Journal of Clinical Pharmacology, Volume 66, Issue 5, May 2026.
Abstract This first‐in‐human study (ClinicalTrials.gov identifier: NCT04472897) evaluated the safety, tolerability, pharmacokinetics, and food effect of single ascending and repeat oral doses of GSK2556286 (GSK286), a novel antitubercular drug candidate with efficacy in animal models of tuberculosis.
Emma Ilsley, Edward Banham‐Hall, Tetyana Chaychenko, Katerina Chinenyeze, Gareth Maher‐Edwards, Catherine Muya, Katie Rolfe, Raman Sharma, Simon Tiberi, David Barros‐Aguirre   +9 more
wiley   +1 more source

Outcomes of Multidrug-Resistant Tuberculosis Treated With Bedaquiline or Delamanid

, 2021
Background. Since 1 September 2016, bedaquiline and delamanid have been administered for the treatment of patients with multidrug-resistant/rifampicin-resistant tuberculosis after the official approval in South Korea.
Hyungseok Kang, Jeon, Doosoo, Yong-Soo Kwon, Hwang, Hyeontaek, Shim, Tae Sun, Yim, Jae-Joon, 심태선, Doosoo Jeon, Jae-Joon Yim, Hyeontaek Hwang, Kang, Hyungseok, Kwon, Yong-Soo   +11 more
core   +1 more source

Clinical outcomes of multidrug-resistant tracheobronchial tuberculosis receiving anti-tuberculosis regimens containing bedaquiline or delamanid

Scientific Reports
The treatment of multidrug-resistant tracheobronchial tuberculosis poses challenges, and research investigating the efficacy of bedaquiline or delamanid as treatment for this condition is limited.
Qing Chen, Tao Huang, Liping Zou, Xianzhen Tang, Zhengyu Shi, Xinwei Wang, Huaige Wu, Jiying Sun, Xiaoli Lu, Li Liang, Liangshuang Jiang, Dafeng Liu, Shenjie Tang, Guihui Wu, Wei He   +14 more
doaj   +1 more source

Efficacy of bedaquiline in the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis

BMC Infectious Diseases, 2021
Background Drug-resistant tuberculosis (DR-TB) remains a major public health concern worldwide. Bedaquiline, a novel diarylquinoline, was added to the WHO-recommended all-oral regimen for patients with multidrug-resistant tuberculosis.
Ming-Gui Wang, Shou-Quan Wu, Jian-Qing He   +2 more
doaj   +1 more source

Effectiveness and Safety of the Regimens Containing Bedaquiline in Patients with TB and HIV-infection

Туберкулез и болезни лёгких
The objective: to analyze effectiveness and safety of bedaquiline administered concurrently with antiretroviral therapy in treatment regimens for patients with such comorbidities as HIV infection and multiple drug resistant and extensively drug resistant
S. B. Borisova, N. Yu. Borodina
doaj   +1 more source

Bactericidal activity against M. leprae THAI53 of bedaquiline administered orally and bedaquiline long-acting measured in Swiss mice by the proportional bactericidal method.

, 2023
Bactericidal activity against M. leprae THAI53 of bedaquiline administered orally and bedaquiline long-acting measured in Swiss mice by the proportional bactericidal method.
Aurélie Chauffour (485000), Koen Andries (346051), Vincent Jarlier (243571), Nacer Lounis (355090), Alexandra Aubry (243572), Nicolas Veziris (321542)   +5 more
core   +1 more source